Reina Haque to Retrospective Studies
This is a "connection" page, showing publications Reina Haque has written about Retrospective Studies.
Connection Strength
1.053
-
Utilization of extended-interval, fixed-dosing of durvalumab, every 4?weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation. Future Oncol. 2026 Jan; 22(1):115-121.
Score: 0.141
-
Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors. Cancer Epidemiol. 2025 Aug; 97:102867.
Score: 0.136
-
Persistent prescription opioid use and all-cause mortality following the first-year breast cancer survivorship. JNCI Cancer Spectr. 2025 Apr 30; 9(3).
Score: 0.135
-
Influence of Comorbidity Burden, Socioeconomic Status, and Race and Ethnicity on Survival Disparities in Patients With Cancer. Cancer Control. 2023 Jan-Dec; 30:10732748231204474.
Score: 0.115
-
Sleep medication use and risk of fractures in breast cancer survivors. Breast Cancer Res Treat. 2021 Dec; 190(3):541-548.
Score: 0.105
-
SARS-CoV-2 Testing, Positivity Rates, and Healthcare Outcomes in a Cohort of 22,481 Breast Cancer Survivors. JCO Clin Cancer Inform. 2021 02; 5:168-175.
Score: 0.101
-
Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc (2003). 2017 May - Jun; 57(3):303-310.e2.
Score: 0.077
-
Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care. 2014; 20(1):86-92.
Score: 0.062
-
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. Cancer Epidemiol Biomarkers Prev. 2013 Feb; 22(2):313-6.
Score: 0.057
-
Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett. 2005 Apr 18; 221(1):61-5.
Score: 0.034
-
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.
Score: 0.019
-
Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619.
Score: 0.018
-
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.
Score: 0.016
-
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.
Score: 0.016
-
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
Score: 0.012
-
Abstracting height and weight from medical records, and breast cancer pathologic factors. Cancer Causes Control. 2008 Dec; 19(10):1217-26.
Score: 0.011